European Archives - Page 538 of 1425 - European Medical Journal

IL-10, IL-6, VEGF, and IL-8 as Independent Prognosticators/Predictors in COVID-19

COVID-19 is a novel β-coronavirus caused by infection with SARS-CoV-2. It is the third zoonotic disease caused by coronavirus to affect…

Right Lateral Digital Rectal Examination in Men with Suspected Prostate Disease

The worldwide prevalence of benign prostatic hyperplasia (BPH) varies between 20–60% in men over 50 years. Similarly, about 50% of men…

Deep Learning for Brain Tumour Analysis

A brain tumour develops as a result of abnormal cell growth in the brain. Tumours are classified as malignant or benign. Malignant tumours…

Obstructive Sleep Apnoea in Sleep Referrals and Related Medical Conditions

Obstructive sleep apnoea (OSA) is a complex and chronic disease characterised by loud snoring, daytime sleepiness, and witnessed breathing…

Gynaecomastia in a Patient with Spinal Cord Injury

Gynaecomastia, the clinical term for the enlargement of the male breast, is characterised by the histological finding of…

From congress to computer: Making on-demand video pop

Video is a powerful tool because it extends the reach of a live event, but does a recording ever live up to the event itself? Enter 3D interactive video.

Does Immunosuppressive Therapy Increase Infection Risk in Older Adults with IBD?

New research from DDW 2024 shows older adults with inflammatory bowel disease treated with advanced therapies may face a slightly increased risk of infection.

Surgery Versus GLP-1 Agonists in Patients with Obesity and Kidney Disease

Metabolic bariatric surgery offers substantial protective benefits for patients with chronic kidney disease, Type 2 diabetes, and obesity, according to new research.

Time-Restricted Eating Improves Glycaemic Control in Adults at Risk of Type 2 Diabetes: EASD 2024

Time-restricted eating, limiting food intake to an 8-hour window, significantly improves blood sugar control in adults at risk of Type 2 diabetes, research from EASD 2024 shows.

Liraglutide Effective for Children with Obesity Aged Under 12 Years: EASD 2024

The SCALE Kids trial has found that weight-loss drug liraglutide is safe and effective for children aged 6 to under 12 years living with obesity.